TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02405923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRF
Description: The subject will take the formula for a period of 12 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: eHF
Description: The subject will take the formula for a period of 12 months.
Study: NCT01123954

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Seasonal flu vaccine
Description: This phase II is performed as a monocenter study site in a population of healthy subjects aged 1 to 45 years. Enrolled subjects received one single IM dose of trivalent subunit inactivated influenza vaccine during the vaccination visit, according to the study protocol (follow-up period: 30 days)
Study: NCT01096212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: original sevoflurane
Description: Sevoflurane content: 99.9985%, compound A: 4.6 ppm, water content (sample was opened, sealed and stored for 2 weeks): 0.072% w/v

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: generic sevoflurane
Description: Sevoflurane content: 99.99%, compound A: 3.8 ppm, water content (sample was opened, sealed and stored for 2 weeks) : 0.044% w/v
Study: NCT00528164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team PLAY
Description: Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
Study: NCT03138811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSJ117
Description: inhaled once daily dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: inhaled once daily dose
Study: NCT04121611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: 1. Intravenous unfractionated heparin (UFH) infusion within 6 hours of EVT with target activated partial thromboplastin time (aPTT) 64-86~2. Anticoagulation to continue for minimum of 48 hours (can be maintained on UFH aPTT 64-86 or transitioned to low-molecular weight heparin (LMWH) Enoxaparin 1mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (ASA)
Description: 1. Acetylsalicylic Acid (ASA) 325mg PO/PR/NG loading dose \< 2 hours of EVT completion~2. ASA 81mg PO OD maintenance dose
Study: NCT00230438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Study: NCT02488187

Intervention type: DEVICE
Group type: OTHER
Intervention: ABUS
Description: Automated breast ultrasound

Intervention type: DEVICE
Group type: OTHER
Intervention: ABUS
Description: Automated breast ultrasound
Study: NCT03597971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL004-6599
Description: For each cohort, 6 subjects will receive HMPL004-6599

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For each cohort, 2 subjects will receive placebo
Study: NCT00659529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.
Study: NCT01681810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14Nitrogen Sodium Nitrite
Description: oral formulation of sodium nitrite 40 mg three times a day for 12 weeks
Study: NCT06211192

Intervention type: OTHER
Intervention: retrospective data collection
Description: retrospective data collecting from medical records

Intervention type: OTHER
Intervention: retrospective data collection
Description: retrospective data collecting from medical records
Study: NCT01288222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KIR genotype
Description: KIR genotype data from unrelated donor are collected
Study: NCT04155268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flotation-REST
Description: Floating in a specialized device (float pod or float cabin) used to attenuate sensory input.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dark Room
Description: Participants will lay on an air mattress in a dark room with no cell phone and reduced sensory input.
Study: NCT02069925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Detection (ED)
Description: This intervention consists of educational campaigns directed at patients \& families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Detection
Description: This intervention will provide equivalent best practice care without the benefit of an early detection campaign

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Detection
Description: This intervention will provide equivalent best practice care without the benefit of an early detection campaign
Study: NCT01768897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01726244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Intervention
Description: Health education sessions consisting in controlling disease and stress asociated to it, and modifying eating habits
Study: NCT04109365

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrical Epidural Stimulation Test (EST)
Description: EST measures sensory/motor responses
Study: NCT01386918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation
Description: The treatment involves the administration of a magnetic field applied to a specific area of the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation
Description: The treatment involves the administration of a magnetic field applied to a specific area of the brain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: The treatment involves the administration of a magnetic field applied to a specific area of the brain.
Study: NCT04196803

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium glycinate
Description: Oral administration of magnesium glycinate daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of identical-appearing placebo daily for 12 weeks
Study: NCT01187069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training course for practice nurses in autonomy support
Description: An interactive course consisting of 4X4 hours education in autonomy support over a 6 months period. The main-components in the course are 1) communication skills, 2) introduction to patient work-sheets and 3) a quick up-to-date knowledge about treatment recommendations of type 2 diabetes. Furthermore, the nurses in the intervention-practices receive a half an hour support-visit 4-5 months after the end of the course.
Study: NCT03881228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing the completion of IPT
Description: Behavioral intervention with three components to increase the completion of IPT among children
Study: NCT00618436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Levetiracetam group will receive a loading dose of 20 mg/kg IV(rounded to nearest 250mg) to a maximum of 2000mg, then started on maintenance dose (1000 mg,IV q 12h) as prophylaxis for seven days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin
Description: The group will receive a loading dose of fosphenytoin 20 mg/kg IV to a maximum of 2000 mg, then started on maintenance dose of 5mg/kg/day, rounded to nearest 100mg dose, IV, q 12h for seven days.
Study: NCT04254588

Intervention type: OTHER
Intervention: Abdominal examination
Description: Examination by in-person physician vs. remote physician.

Intervention type: OTHER
Intervention: Abdominal examination
Description: Examination by in-person physician vs. remote physician.
Study: NCT01231256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive health consultation
Description: A one hour preventive health consultation, based on completed baseline questionnaire, with one or two goal setting for a better life during the next year, with discussion and registration of resources, barriers, and time scheme. And a 3 month follow up consultation.
Study: NCT05370716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polmacoxib
Description: Polmacoxib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polmacoxib
Description: Polmacoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin
Study: NCT04465448

Intervention type: OTHER
Intervention: MRI
Description: Those included will perform an MRI without injection to obtain the QSM then they will exit the machine and reinstall themselves there to perform the second measurement. They will then change the MRI machine to perform a third measurement

Intervention type: OTHER
Intervention: MRI
Description: Those included will perform an MRI without injection to obtain the QSM then they will exit the machine and reinstall themselves there to perform the second measurement. They will then change the MRI machine to perform a third measurement
Study: NCT03173066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: ferumoxytol-enhanced magnetic resonance angiography for the diagnosis of pulmonary embolus
Study: NCT03374995

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Topical Keratin
Description: Given topically
Study: NCT00044551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxane (Cytotoxic, BAY59-8862)
Description: Daily 1 h infusion every 3 weeks
Study: NCT03517189

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aorta no-touch
Description: Participants will be submitted to aorta no-touch off-pump coronary artery bypass surgery.
Study: NCT02091154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: USDA Regulations
Description: Implement new USDA regulations assigned school cafeterias.~1. Fruit or vegetable on every tray~2. Meet requirements for vegetable varieties~3. 50% of all grains must be whole grain~4. Milk must be 1% or skim; flavored milk must be skim

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: USDA Regulations
Description: Implement new USDA regulations assigned school cafeterias.~1. Fruit or vegetable on every tray~2. Meet requirements for vegetable varieties~3. 50% of all grains must be whole grain~4. Milk must be 1% or skim; flavored milk must be skim

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: USDA Regulations
Description: Implement new USDA regulations assigned school cafeterias.~1. Fruit or vegetable on every tray~2. Meet requirements for vegetable varieties~3. 50% of all grains must be whole grain~4. Milk must be 1% or skim; flavored milk must be skim

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Marketing Kit
Description: This marketing tool kit is designed to encourage purchasing of school lunches. The marketing tool kit included the following components:~1. 56''x72'' vinyl sign with the words \[school mascot\] Cafe~2. 8.5''x11'' signs describing the foods offered on a specific day~3. 2''x4'' signs used to name all foods. These were to be placed in a visible location near the corresponding food.~4. Magnetic board displaying a tray onto which magnets shaped as food can be placed to show what foods were being offered during a specific lunch shift.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smarter Lunchrooms Makeover (SLM)
Description: Implement three basic Smarter Lunchrooms techniques. It consists of the following components:~1. Place fruit in an attractive bowl or serving dish and set on two places on the line. One of the places should be at or near the register.~2. Give all vegetables descriptive names and write or type them on a 2''x4'' card. These cards should be visible and placed near the corresponding food.~3. Make white milk the most prominent milk in the milk coolers by making it the most available milk and easiest to take.
Study: NCT03684590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANI-guided opioid administration
Description: Intraoperative opioid will be administered guided by analgesia nociceptive index (ANI) values measured by ANI monitor (MetroDoloris Medical Systems, Lille, France)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard opioid administration
Description: Intraoperative opioid will be administered according to standard practice during surgery.
Study: NCT03540472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: On refractory PRCA patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study
Study: NCT01927328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron isomaltoside 1000
Study: NCT03442790

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Agitated Saline Method
Description: All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using agitated saline under ultrasound vision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Agitated Saline Method
Description: All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using agitated saline under ultrasound vision.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chest x-ray
Description: All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using chest x-ray obtained in supine position as an active comparator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chest x-ray
Description: All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using chest x-ray obtained in supine position as an active comparator
Study: NCT04304976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROBERT®
Description: Robotic Rehabilitation intervention ROBERT®, designed for early, and supplementary therapy of patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROBERT®
Description: Robotic Rehabilitation intervention ROBERT®, designed for early, and supplementary therapy of patients.
Study: NCT04014036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low energy extracorporeal shockwave therapy
Description: Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: low energy extracorporeal shockwave therapy
Description: Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
Study: NCT01994239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Radiotherapy
Description: 46 Gy in 23 fractions Prostate only-boost up to 66 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic Radiotherapy
Description: 46 Gy in 23 fractions Prostate only-boost up to 66 Gy
Study: NCT03152279

Intervention type: DIAGNOSTIC_TEST
Intervention: Mucosal Impedance Catheter
Description: During routine endoscopy, consented study participants will have a mucosal impedance catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: Mucosal Impedance Catheter
Description: During routine endoscopy, consented study participants will have a mucosal impedance catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: At time of endoscopy, subjects with initial positive CeD serology will have a blood sample taken for any missing CeD serologies and intestinal fatty acid-binding protein (IFABP). This will be done at time of IV initiation as to avoid any additional venipuncture.
Study: NCT02885948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: used to block the effects of opioids, especially in overdose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, ineffective control arm
Study: NCT03341741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin Powder
Description: TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off);

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: Colistin solution 2 x daily 1 Mega continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: Colistin solution 2 x daily 1 Mega continuously
Study: NCT00774813

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nexalin 1.3mA Device
Description: * 3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~* Daily receipt of placebo antidepressant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nexalin 15mA device
Description: * 3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~* Daily receipt of a placebo antidepressant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo device and Citalopram
Description: * 3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~* Daily receipt of a a SSRI (Citalopram or similar)
Study: NCT02412020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PA101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00805662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin, placebo
Description: intranasal oxytocin during intrauterine insemination
Study: NCT02575040

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation to patients with ulcerative colitis and Crohn disease
Study: NCT03269643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Group
Description: The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reference group
Description: The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
Study: NCT00550654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Patients complete a pain assessment questionnaire, Brief Pain Inventory at baseline and at 1 and 3 months after treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Conformal radiation therapy improves the ability to spare normal tissues.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: Hypofractionated radiation therapy is delivered to maximize pain relief while minimizing patient impact if life expectancy is short.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: image-guided radiation therapy
Description: Image guided radiation therapy targets the specific site of disease.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: Tomotherapy is a delivery method which provides megavoltage computed tomography (CT) localization and may provide superior conformality and localization compared to other dynamic intensity modulated radiation therapy techniques.
Study: NCT03829241

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Troriluzole
Description: 100 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troriluzole
Description: 100 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to troriluzole
Study: NCT00698451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin HCL liposome; bevacizumab; carboplatin
Description: 30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
Study: NCT01179672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 30 mg administered orally (po), QD for 1 week; 60 mg administered po, QD for remaining 11 weeks; 30 mg administered po, QD for 1 week during taper period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered po, QD for 12 weeks; administered po, QD for 1 week during taper period